242 related articles for article (PubMed ID: 35339868)
21. Evolution of treatment strategies for oligometastatic NSCLC patients - A systematic review of the literature.
Schanne DH; Heitmann J; Guckenberger M; Andratschke NHJ
Cancer Treat Rev; 2019 Nov; 80():101892. PubMed ID: 31522079
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic body radiation therapy for metastatic lung metastases.
Kimura T; Fujiwara T; Kameoka T; Adachi Y; Kariya S
Jpn J Radiol; 2022 Oct; 40(10):995-1005. PubMed ID: 36097233
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
24. Defining Oligometastatic Bladder Cancer: A Systematic Review.
Bamias A; Stenzl A; Zagouri F; Andrikopoulou A; Hoskin P
Eur Urol Open Sci; 2023 Sep; 55():28-37. PubMed ID: 37662704
[TBL] [Abstract][Full Text] [Related]
25. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic radiotherapy in oligometastatic cancer.
Kennedy TAC; Corkum MT; Louie AV
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
[TBL] [Abstract][Full Text] [Related]
27. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?
Widder J; Klinkenberg TJ; Ubbels JF; Wiegman EM; Groen HJ; Langendijk JA
Radiother Oncol; 2013 Jun; 107(3):409-13. PubMed ID: 23773410
[TBL] [Abstract][Full Text] [Related]
28. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
29. Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.
Baker S; Mou B; Jiang W; Liu M; Bergman AM; Schellenberg D; Alexander AS; Carolan H; Atrchian S; Berrang T; Bang A; Chng N; Matthews Q; Tyldesley S; Olson RA
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):849-855. PubMed ID: 36302495
[TBL] [Abstract][Full Text] [Related]
30. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road.
Depypere L; Lerut T; Moons J; Coosemans W; Decker G; Van Veer H; De Leyn P; Nafteux P
Dis Esophagus; 2017 Jan; 30(1):1-8. PubMed ID: 27704661
[TBL] [Abstract][Full Text] [Related]
31. A critical review on oligometastatic disease: a radiation oncologist's perspective.
Pacifico P; Colciago RR; De Felice F; Boldrini L; Salvestrini V; Nardone V; Desideri I; Greco C; Arcangeli S
Med Oncol; 2022 Sep; 39(12):181. PubMed ID: 36071292
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
33. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study.
Milano MT; Katz AW; Zhang H; Okunieff P
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):878-86. PubMed ID: 22172903
[TBL] [Abstract][Full Text] [Related]
34. Oligometastasis in breast cancer-current status and treatment options from a radiation oncology perspective.
Piroth MD; Krug D; Feyer P; Baumann R; Combs S; Duma MN; Dunst J; Fastner G; Fietkau R; Guckenberger M; Haase W; Harms W; Hehr T; Sedlmayer F; Souchon R; Strnad V; Budach W
Strahlenther Onkol; 2022 Jul; 198(7):601-611. PubMed ID: 35527272
[TBL] [Abstract][Full Text] [Related]
35. Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
Frost N; Tessmer A; Schmittel A; van Laak V; Raspe M; Ruwwe-Glösenkamp C; Brunn M; Senger C; Böhmer D; Ochsenreither S; Temmesfeld-Wollbrück B; Furth C; Schmidt B; Neudecker J; Rückert JC; Suttorp N; Witzenrath M; Grohé C
Lung Cancer; 2018 Nov; 125():164-173. PubMed ID: 30429016
[TBL] [Abstract][Full Text] [Related]
36. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
Franzese C; Badalamenti M; Teriaca A; De Virgilio A; Mercante G; Cavina R; Ferrari D; Santoro A; Spriano G; Scorsetti M
J Cancer Res Clin Oncol; 2021 May; 147(5):1307-1313. PubMed ID: 33471186
[TBL] [Abstract][Full Text] [Related]
37. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
Moretto R; Rossini D; Zucchelli G; Lonardi S; Bergamo F; Santini D; Cupini S; Tomasello G; Caponnetto S; Zaniboni A; Antoniotti C; Pietrantonio F; Buonadonna A; Marmorino F; Bordonaro R; Fea E; Tamburini E; Boccaccino A; Grande R; Aprile G; Falcone A; Cremolini C
Eur J Cancer; 2020 Nov; 139():81-89. PubMed ID: 32979645
[TBL] [Abstract][Full Text] [Related]
38. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III Disease.
Guberina M; Pöttgen C; Guberina N; Hoffmann C; Wiesweg M; Richlitzki C; Metzenmacher M; Aigner C; Bölükbas S; Gauler T; Eberhardt WEE; Forsting M; Herrmann K; Theegarten D; Darwiche K; Jendrossek V; Stuschke M; Schuler M
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539510
[No Abstract] [Full Text] [Related]
40. Oligometastatic head and neck cancer: Comprehensive review.
Vengaloor Thomas T; Packianathan S; Bhanat E; Albert A; Abraham A; Gordy X; Kanakamedala M; Mehta D; Vijayakumar S
Head Neck; 2020 Aug; 42(8):2194-2201. PubMed ID: 32220043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
